IP Library Granted Patent US 8,563,509
Granted Patent B2
US 8,563,509 · App. 11/927,235 · Granted Oct 22, 2013

Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates

Inventors: Ravi Chari (Newton, MA); Wayne Widdison (Somerville, MA)
Assignee: Immunogen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,509
App. No.
11/927,235
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

Claims (8)

1. A compound of formula 5:

wherein X is a linear or branched alkyl, alkenyl or alkynyl group bearing 2 to 20 carbon atoms, Y is a cycloalkyl or cycloalkenyl group bearing 3 to 10 carbon atoms, Z is an aromatic group having 6 to 10 carbon atoms and optionally substituted with at least one alkyl substituent containing from 1 to 4 carbon atoms, alkoxy substituent containing one or two carbon atoms, halogen or nitro group or a heterocyclic group having a 3 to 10-membered ring system containing one or two heteroatoms selected from N, O or S and optionally substituted with one or two nitro group, and l, m and n are each 0 or 1, provided that they are all not 0 at the same time, and E together with the adjacent carbonyl group forms an activated ester.

2. A compound of formula 6:

wherein n′ represents an integer from 3 to 24, and E together with the adjacent carbonyl group forms an activated ester.

3. A compound of formula 7:

wherein R is H or SO 3 − Na + .

4. The compound of claim 1 , wherein the activated ester is an N-hydroxy succinimidyl ester, an N-hydroxy sulfosuccinimidyl ester, an N-hydroxy phthalimidyl ester, an N-hydroxy sulfophthalimidyl ester, an ortho-nitrophenyl ester, a para-nitrophenyl ester, a 2,4-dinitrophenyl ester, a 3-sulfonyl-4-nitrophenyl ester, a 3-carboxy-4-nitrophenyl ester, a pentafluorophenyl ester, or a sulfonyl tetrafluorophenyl ester.

5. The compound of claim 2 , wherein the activated ester is an N-hydroxy succinimidyl ester, an N-hydroxy sulfosuccinimidyl ester, an N-hydroxy phthalimidyl ester, an N -hydroxy sulfophthalimidyl ester, an ortho-nitrophenyl ester, a para-nitrophenyl ester, a 2,4-dinitrophenyl ester, a 3-sulfonyl-4-nitrophenyl ester, a 3-carboxy-4-nitrophenyl ester, a pentafluorophenyl ester, or a sulfonyl tetrafluorophenyl ester.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2011
From: WIDDISON, WAYNE C.
To: IMMUNOGEN INC.
Reel/Frame 026749/0186 →
ADDRESS CHANGE Recorded May 13, 2008
From: IMMUNOGEN, INC.
To: IMMUNOGEN, INC.
Reel/Frame 020930/0905 →
Continuity (2)
Division 10960602 · Oct 8, 2003
Related Publication 20080171865A1 · Jul 17, 2008